New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE From The Last 14 Days
Check below for free stories on BMY;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 22, 2013
16:00 EDTBMYOptions Update; May 22, 2013
Subscribe for More Information
10:33 EDTBMYBristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information
10:16 EDTBMYBristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information
10:00 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:59 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTPFEZoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information
08:04 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
08:02 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
06:05 EDTBMYBristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
May 21, 2013
07:34 EDTBMYUBS to host a conference
Subscribe for More Information
07:24 EDTBMYGlobal Health Care to host a conference
Subscribe for More Information
07:16 EDTPFEPfizer management to meet with Leerink
Subscribe for More Information
May 20, 2013
17:04 EDTPFEPfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information
10:03 EDTBMYShire advances after report renews takeover speculation
Subscribe for More Information
06:30 EDTBMYLeerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire.
06:25 EDTBMYShire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information
May 17, 2013
13:21 EDTBMYOptions with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information
May 16, 2013
16:32 EDTBMYBristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information
13:20 EDTBMYFollow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares.
13:14 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.